Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other financing activities (2019 - 2023)

10x Genomics (TXG) has disclosed Other financing activities for 5 consecutive years, with $5.8 million as the latest value for Q1 2023.

  • Quarterly Other financing activities rose 7.49% to $5.8 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2023, up 7.49% year-over-year, with the annual reading at $5.8 million for FY2023, 7.49% up from the prior year.
  • Other financing activities hit $5.8 million in Q1 2023 for 10x Genomics, up from $5.4 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $5.8 million in Q1 2020 to a low of -$1.9 million in Q3 2019.
  • Historically, Other financing activities has averaged $3.2 million across 5 years, with a median of $5.0 million in 2021.
  • Biggest five-year swings in Other financing activities: decreased 13.99% in 2021 and later grew 7.58% in 2022.
  • Year by year, Other financing activities stood at -$1.9 million in 2019, then skyrocketed by 100.1% to $2000.0 in 2020, then skyrocketed by 251300.0% to $5.0 million in 2021, then grew by 7.58% to $5.4 million in 2022, then grew by 7.49% to $5.8 million in 2023.
  • Business Quant data shows Other financing activities for TXG at $5.8 million in Q1 2023, $5.4 million in Q1 2022, and $5.0 million in Q1 2021.